CN102834097B - 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法 - Google Patents

纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法 Download PDF

Info

Publication number
CN102834097B
CN102834097B CN201080064457.9A CN201080064457A CN102834097B CN 102834097 B CN102834097 B CN 102834097B CN 201080064457 A CN201080064457 A CN 201080064457A CN 102834097 B CN102834097 B CN 102834097B
Authority
CN
China
Prior art keywords
dihydro
pyrrolo
trans
dione
quinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080064457.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102834097A (zh
Inventor
D.P.里德
N.R.巴恩斯
J.C.凯恩
C.A.李
J.陈
M.P.雷蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Priority to CN201510243421.1A priority Critical patent/CN104910159A/zh
Publication of CN102834097A publication Critical patent/CN102834097A/zh
Application granted granted Critical
Publication of CN102834097B publication Critical patent/CN102834097B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201080064457.9A 2009-12-23 2010-12-21 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法 Active CN102834097B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510243421.1A CN104910159A (zh) 2009-12-23 2010-12-21 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28956309P 2009-12-23 2009-12-23
US61/289563 2009-12-23
PCT/US2010/061625 WO2011079142A2 (en) 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510243421.1A Division CN104910159A (zh) 2009-12-23 2010-12-21 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法

Publications (2)

Publication Number Publication Date
CN102834097A CN102834097A (zh) 2012-12-19
CN102834097B true CN102834097B (zh) 2015-06-17

Family

ID=44188284

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080064457.9A Active CN102834097B (zh) 2009-12-23 2010-12-21 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法
CN201510243421.1A Pending CN104910159A (zh) 2009-12-23 2010-12-21 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510243421.1A Pending CN104910159A (zh) 2009-12-23 2010-12-21 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法

Country Status (19)

Country Link
US (3) US8552192B2 (enExample)
EP (2) EP2515904A4 (enExample)
JP (2) JP2013515737A (enExample)
KR (2) KR20160121602A (enExample)
CN (2) CN102834097B (enExample)
AU (2) AU2010336533B9 (enExample)
BR (1) BR112012015656A2 (enExample)
CA (1) CA2785503A1 (enExample)
CO (1) CO6561823A2 (enExample)
HK (1) HK1215025A1 (enExample)
MX (1) MX2012007259A (enExample)
MY (2) MY156701A (enExample)
NZ (2) NZ628087A (enExample)
PH (2) PH12012501293A1 (enExample)
RU (1) RU2556205C2 (enExample)
SG (1) SG181927A1 (enExample)
TW (3) TWI557125B (enExample)
WO (1) WO2011079142A2 (enExample)
ZA (1) ZA201204759B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2409579C2 (ru) * 2005-02-09 2011-01-20 Аркьюл, Инк. Композиции и способы лечения рака
PH12012501293A1 (en) * 2009-12-23 2013-01-07 Arqule Inc Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
MX2014000253A (es) 2011-07-07 2014-10-17 Arqule Inc Formulaciones de pirroloquinolinil-pirrolidin-2,5-diona y metodos para preparar y utilizar las mismas.
AU2013252944B2 (en) * 2012-04-23 2017-04-13 Arqule, Inc. Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same
EP3021849B1 (en) * 2013-07-16 2019-10-09 Dr. Reddy's Laboratories Ltd. Novel crystalline forms of pemetrexed tromethamine salts
DK3665176T3 (da) * 2017-08-11 2024-03-25 Actuate Therapeutics Inc Faste former af 3-(5-fluorbenzofuran-3-yl)-4-(5-methyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrol-2,5-dion
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
IL307471A (en) * 2021-04-07 2023-12-01 Ur 1 Therapeutics Inc URAT1 inhibitor, pharmaceutical preparations and their uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060223760A1 (en) * 2005-02-09 2006-10-05 Li Chiang J Compositions and methods for treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE4128015A1 (de) * 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
US5760237A (en) * 1995-08-25 1998-06-02 California Institute Of Technology Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary
EP1242420A2 (en) * 1999-12-16 2002-09-25 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
AU2003249490A1 (en) * 2002-07-31 2004-02-23 Firmenich Sa A process for the optical resolution of a precursor of sclareolide
EP1786772A1 (en) * 2004-09-10 2007-05-23 Wyeth a Corporation of the State of Delaware Process for the scalable synthesis of 1, 3, 4, 9-tetrahydropyranoý3, 4-b¨-indole derivatives
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
CA2690782C (en) * 2007-06-22 2016-02-02 Arqule, Inc. Compositions and methods for treatment of cancer
JP5425060B2 (ja) 2007-06-22 2014-02-26 アークル インコーポレイテッド ピロリジノン、ピロリジン−２，５−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法
PH12012501293A1 (en) * 2009-12-23 2013-01-07 Arqule Inc Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
AU2013252944B2 (en) * 2012-04-23 2017-04-13 Arqule, Inc. Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060223760A1 (en) * 2005-02-09 2006-10-05 Li Chiang J Compositions and methods for treatment of cancer

Also Published As

Publication number Publication date
JP2013515737A (ja) 2013-05-09
TWI506026B (zh) 2015-11-01
US20110160242A1 (en) 2011-06-30
MY169232A (en) 2019-03-19
TW201643163A (zh) 2016-12-16
SG181927A1 (en) 2012-07-30
EP3081567A2 (en) 2016-10-19
KR20120113760A (ko) 2012-10-15
EP3081567A3 (en) 2016-11-16
AU2010336533A1 (en) 2012-07-12
EP2515904A2 (en) 2012-10-31
RU2556205C2 (ru) 2015-07-10
US8552192B2 (en) 2013-10-08
CA2785503A1 (en) 2011-06-30
WO2011079142A3 (en) 2011-11-24
MX2012007259A (es) 2015-05-15
AU2015243015B2 (en) 2017-02-02
CN104910159A (zh) 2015-09-16
NZ628087A (en) 2016-02-26
AU2015243015A1 (en) 2015-11-05
HK1215025A1 (zh) 2016-08-12
JP2016041712A (ja) 2016-03-31
US8871933B2 (en) 2014-10-28
RU2012131344A (ru) 2014-01-27
WO2011079142A2 (en) 2011-06-30
US20160024076A1 (en) 2016-01-28
EP2515904A4 (en) 2013-07-03
CN102834097A (zh) 2012-12-19
TW201141865A (en) 2011-12-01
BR112012015656A2 (pt) 2016-05-10
MY156701A (en) 2016-03-15
ZA201204759B (en) 2014-03-26
PH12014500310A1 (en) 2015-09-28
PH12012501293A1 (en) 2013-01-07
TW201542546A (zh) 2015-11-16
TWI557125B (zh) 2016-11-11
US9499540B2 (en) 2016-11-22
AU2010336533B2 (en) 2015-09-10
KR20160121602A (ko) 2016-10-19
CO6561823A2 (es) 2012-11-15
AU2010336533B9 (en) 2015-10-08
US20140031551A1 (en) 2014-01-30
KR101669707B1 (ko) 2016-10-27
NZ600800A (en) 2014-10-31

Similar Documents

Publication Publication Date Title
CN102834097B (zh) 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法
CN103282365B (zh) 结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐
CN107074769B (zh) 用于治疗增生性病症的组合物和方法
CN101133055A (zh) 用于治疗癌症的meleimide衍生物、药物组合物以及方法
EP4353724A1 (en) Compound as cdk kinase inhibitor and use thereof
JP2021504332A (ja) ピラゾロピリジノン化合物
US8343977B2 (en) Substituted triazolo-pyrimidine compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant